BCMA-targeted immunotherapy for multiple myeloma.
J Hematol Oncol
; 13(1): 125, 2020 09 17.
Article
en En
| MEDLINE
| ID: mdl-32943087
ABSTRACT
B cell maturation antigen (BCMA) is a novel treatment target for multiple myeloma (MM) due to its highly selective expression in malignant plasma cells (PCs). Multiple BCMA-targeted therapeutics, including antibody-drug conjugates (ADC), chimeric antigen receptor (CAR)-T cells, and bispecific T cell engagers (BiTE), have achieved remarkable clinical response in patients with relapsed and refractory MM. Belantamab mafodotin-blmf (GSK2857916), a BCMA-targeted ADC, has just been approved for highly refractory MM. In this article, we summarized the molecular and physiological properties of BCMA as well as BCMA-targeted immunotherapeutic agents in different stages of clinical development.
Palabras clave
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Antígeno de Maduración de Linfocitos B
/
Terapia Molecular Dirigida
/
Inmunoterapia
/
Mieloma Múltiple
/
Proteínas de Neoplasias
Tipo de estudio:
Clinical_trials
Límite:
Humans
Idioma:
En
Año:
2020
Tipo del documento:
Article